Figure 5.

Silibinin feeding inhibits TRAMPC1 allograft growth in C57Bl/6 mice via targeting immune cells recruitment, bone precursor molecules and activated fibroblast. Male C57Bl/6 mice were injected subcutaneously with 2.5×10⁶ million TRAMPC1 cells in each flank and treated six times a week (once daily) with silibinin (200mg/kg body weight) or vehicle (0.5% CMC) for 66 days. (A) Tumor volume was measured as described in Methods. (B) Tumor mass was determined upon mouse sacrifice (*P ≤ 0.05; **P ≤ 0.01). (C and D) Allografts were collected, sectioned and analyzed by immunohistochemistry for MCP-1, F4/80, Ly6g, CD3, osteocalcin, collagen I, α-smooth muscle actin, fibroblast activation protein, vimentin and TGFβ2. Data shown in bar diagrams represent mean ± SEM of immunoreactivity scores for 10 randomly selected 400× fields/sample from 3 samples for each group (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.005).